Published online before print February 28, 2002, doi: 10.1161/01.ATV.0000014221.30108.08
© 2002 American Heart Association, Inc.
Vascular Biology |
Homocysteine Upregulates Vascular Cell Adhesion Molecule-1 Expression in Cultured Human Aortic Endothelial Cells and Enhances Monocyte Adhesion
From the Laboratory of Cell Biology (M.D.S., R.J.T., M.D., P.I.L.), Department of Medicine, University of Wisconsin Medical School, Milwaukee; the Department of Cell and Developmental Biology and the Department of Ophthalmology (M.D.S., J.T.R.), Oregon Health Sciences University, Portland; the Laboratory of Cell Biology (G.L., P.I.L.), Department of Medicine, University of Wisconsin Medical School, Madison; and the School of Biomedical Engineering, Science, and Health Systems (P.I.L.), Drexel University, Philadelphia, Pa.
Correspondence to Peter I. Lelkes, PhD, School of Biomedical Engineering, Science and Health Systems, Drexel University, Commonwealth Hall 7-721, 3141 Chestnut St, Philadelphia, PA 19104. E-mail pilelkes@ drexel.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Elevated plasma homocysteine is an independent risk factor for atherosclerosis. We hypothesized that homocysteine enhances monocyte/human aortic endothelial cell (HAEC) interactions, a pivotal early event in atherogenesis, by upregulating endothelial adhesion molecules. After incubation of cultured HAECs with reduced DL-homocysteine for up to 24 hours, adhesion of human monocytes to homocysteine-stimulated HAECs was significantly upregulated in a time- and dose-dependent fashion. Pretreatment of HAECs with 100 µmol/L homocysteine caused a 4.5-fold increase in the adhesion of normal human monocytes (P<0.001). Similarly, adhesion of monocytic U937 cells was maximally elevated by 3.5-fold at 100 µmol/L homocysteine (P<0.001). In support of our hypothesis, vascular cell adhesion molecule (VCAM)-1 mRNA expression increased 5-fold in HAECs after 3 hours of treatment with 100 µ mol/L homocysteine, as assessed by quantitative reverse transcription– polymerase chain reaction. Neutralizing antibody studies confirmed the involvement of VCAM-1 in mediating monocyte adhesion to homocysteine-stimulated HAECs. Coincubation of HAECs with homocysteine and tumor necrosis factor-
synergistically elevated monocyte adhesion as well as VCAM-1 protein expression, with the latter evaluated by flow cytometry. Preincubation of HAECs with cyclooxygenase inhibitors completely abrogated homocysteine-induced monocyte adhesion, whereas scavenging reactive oxygen species and the elevation of NO caused partial inhibition only. These data support the notion that the proinflammatory effects of homocysteine may have important implications in atherogenesis.
Key Words: human aortic endothelial cells • homocysteine • monocyte adhesion • vascular cell adhesion molecule-1 • cyclooxygenase
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Homocysteine (Hcy) is a sulfhydryl amino acid metabolite of dietary methionine. Elevated plasma Hcy is an independent cardiovascular risk factor that is associated with accelerated atherosclerosis and increased cerebrovascular/ischemic heart disease.1 Without intervention, nearly 50% of the patients with congenital hyperhomocystinuria (ie, total plasma Hcy [ tHcy] levels >200 µmol/L versus 7 to 14 µmol/L in normal individuals) will experience a major cardiovascular event by the age of 30 years.2 However, more frequently seen in the general population are modestly elevated tHcy levels, which are nonetheless strong predictors of existent and future development of vascular pathologies.3
Elevated Hcy appears to contribute to cardiovascular disease, in part, by inducing endothelial cell (EC) dysfunction. In vivo, moderately elevated tHcy causes EC damage,4 exacerbates hypertension-related atherosclerosis,4 and impairs flow-mediated arterial dilation.5 In vitro, Hcy-thiolactone is cytotoxic to ECs,6 and the free reduced thiol (HcyH) alters the endothelial expression of bioactive molecules, such as NO, interleukin (IL)-8, and tissue factor.7,8 Additionally, HcyH increases leukocyte adhesion to cultured human umbilical vein ECs,9 and elevated tHcy induces adhesion molecule expression and leukocyte adhesion in rodent aortas.10
Atherosclerosis is a chronic low-grade inflammatory disorder11 in which the adhesion of monocytes to the vascular endothelium and their subsequent migration into the vessel wall are pivotal early events in pathogenesis. Experimental evidence strongly implicates sustained elevated EC expression of adhesion molecules, such as vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, and E-selectin, as mediators of the subintimal leukocyte accumulation in atherosclerosis.11 In the present study, we tested the hypothesis that HcyH increases monocyte adhesion to cultured human ECs by upregulating the expression of adhesion molecules on the EC surface. Our results suggest that even moderately elevated HcyH is proinflammatory and upregulates the endothelial expression of VCAM-1. HcyH-induced EC activation is dependent on endothelial cyclooxygenase (COX) activity and is modulated by endothelium-derived NO and reactive oxygen species (ROS).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Recombinant human tumor necrosis factor (TNF)-
, anti-human IL-1, polyclonal neutralizing antibody, and anti–VCAM-1 monoclonal antibody (clone BBIG-V1) were from R&D Systems Inc. Anti-human ICAM-1 (clone RR1/1.1.1) and anti-human E-selectin (clone CL26C10B7) monoclonal antibodies were gifts from Boehringer-Ingelheim, Inc. FITC-labeled monoclonal anti-human VCAM-1 antibody (clone 1.G11B1) was from Ancell Immunological Research Products. NS-398 was from Calbiochem, Inc. FCS was from Hyclone Laboratories Inc. EGM-2 Bulletkit growth factor kits were from Clonetics, Inc. Reduced DL-homocysteine (HcyH, as distinguished from total plasma homocysteine [tHcy] or the generic abbreviation for any homocysteine form [Hcy]), culture media MCDB-131 and RPMI-1640, and all other reagents were from Sigma Chemical Co. Cell culture media and all stock solutions had no detectable endotoxin contamination (E-Toxate kit, Sigma).
Cell Isolation and Culture
Human aortic ECs (HAECs), isolated according to Institutional Review Board approved protocols as previously described,12 were cultured in medium MCDB-131/medium 199 (1:1) containing 10% FCS, EGM-2 growth factor supplements (hydrocortisone omitted), 10 µg/mL gentamicin, and 125 ng/mL fungizone (complete medium) at 37°C in a 5% CO2/95% air (100% humidity) atmosphere. HAECs were used at passages 5 to 10. Normal human monocytes were isolated with a commercially available kit (Miltenyi Biotec) from blood donated by apparently healthy laboratory personnel according to IRB-approved protocols, and purity was verified to be >95% by cytostaining for morphology and nuclear structure. Monocytes were maintained in MCDB-131/10% FCS and immediately used in adhesion experiments. Human monocytic U937 cells (American Type Culture Collection) were propagated in RPMI-1640/10% FCS and switched into MCDB-131/10% FCS the day before the adhesion assays were performed.
Monocyte Adhesion Assays
Confluent HAEC monolayers grown in 24-well tissue culture plates were incubated for up to 24 hours with 0 to 1000 µmol/L HcyH added from freshly prepared 100x stock solutions in complete medium. Control wells received only vehicle. Cysteine was used as a negative control, and TNF- was added as a positive control for adhesion molecule induction. To test the possible involvement of diverse intracellular effectors, appropriate pharmacological modulators (detailed below) were administered 30 minutes before HcyH. After HAEC stimulation and washing, 2.5x105 monocytes per well were added and allowed to attach at 37°C for 30 minutes. After 3 washes with complete medium, cultures were fixed (0.5% glutaraldehyde/PBS), and attached monocytes were counted on an inverted microscope. Four randomly chosen 1-mm2 regions in each of quadruplicate wells per condition were evaluated. In some cases, saturating concentrations of neutralizing monoclonal antibodies against ICAM-1, VCAM-1, and E-selectin were added to the HAEC monolayers during the final 30 minutes of the HcyH stimulation, before the monocytes were added. Preliminary antibody dose-response assays verified saturating neutralizing concentrations.
Flow Cytometry
Confluent HAEC monolayers in 12-well plates were stimulated overnight with 0 to 100 µmol/L HcyH, as described above. In some wells, TNF- (0.1 to 10.0 ng/mL) was added 5 hours before experimental termination. Cells were gently dislodged by brief trypsinization (0.025% [wt/vol] trypsin and 2 mmol/L EDTA in PBS), neutralized and blocked with complete medium, stained with FITC-labeled monoclonal anti–VCAM-1 antibody, and fixed with 2% glutaraldehyde, and cell surface VCAM-1 expression was evaluated by flow cytometry in a FACscan II (Beckton Dickinson, Inc). Ten thousand cells were analyzed per sample by using WinMDI software. Data are expressed as the percentage of VCAM-1–positive cells, after subtracting the small contribution of HAEC autofluorescence. Duplicate samples were evaluated in 4 experiments.
Competitive Quantitative Reverse Transcription–PCR
Adhesion molecule mRNA levels were evaluated by using a quantitative polymerase chain reaction (PCR) assay, as previously detailed.12 Briefly, human-specific ICAM-1 and VCAM-1 primers were synthesized by using the published sequences.13,14 Internal standards were constructed in plasmid vectors by deleting an internal 123- and 231-bp fragment from the targeted cDNA sequence for ICAM-1 and VCAM-1, respectively. Coamplification of constant amounts of cDNA with serial dilutions of internal standards and comparison of relative band densities allowed the precise determination of target message amounts present in HAECs.12 Band intensities were compared by using Mocha 1.2.10 Image Analysis software (Jandel Corp). Results are presented as picomole equivalents of internal standard concentrations.
Statistical Analysis
Results are expressed as mean±SD for the indicated number of experiments. The significance of variability among the experimental group means was determined by 1-way ANOVA with the use of SigmaStat 2.0 software (Jandel Corp). Differences between experimental groups were considered to be statistically significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Enhanced Monocyte Adhesion in HcyH- Stimulated ECs
HcyH treatment (18 hours) caused a concentration-dependent increase in the adhesion of monocytic U937 cells to HAEC monolayers (Figure 1). Background U937 monocyte adhesion to unstimulated HAEC monolayers was 9±1 cells/mm2 (n=34 experiments conducted in quadruplicate wells per experiment). By use of U937 monocytes, stimulation of HAECs with 10 µmol/L HcyH (the concentration of tHcy typically present in the circulation of normal individuals)1–3 caused no difference in adhesion versus that in unstimulated control cells (10±2 cells/mm2, P=0.279; n=6). However, at higher concentrations, which were representative of moderate (15 to 30 µ mol/L) to severe (>30 µmol/L) hyperhomocysteinemia, a significantly increase in monocyte adhesion was observed. This effect was obvious at 20 µ mol/L HcyH (17±4 cells/mm2, P=0.007; n=3), and was maximal at 100 µmol/L HcyH (35±7 cells/mm2, P<0.001; n=33). Monocyte adhesion remained elevated at concentrations up to 300 µmol/L HcyH (26±10 cells/mm2, n=4). At higher concentrations, HcyH was cytotoxic to HAECs, as inferred from enhanced trypan blue uptake, increased LDH release, and disorganization of the EC monolayer with cell rounding and detachment (not shown).
|
20 µmol/L significantly increased adhesion, being maximal at 100 µ mol/L (n=2 to 33 experiments). Cysteine had no effect (n=3). With 100 µmol/L Hcy, increased adhesion was observed after 4 hours (inset), reached a maximum after 12 to 18 hours of stimulation, and was maintained through 24 hours (n=2). *P<0.05 vs control cells.
Background adhesion of normal human peripheral blood monocytes was 26±6 monocytes/mm2 (n=3, Figure 2), likely reflecting mild activation during isolation. Adhesion of normal monocytes to HAECs stimulated with 200 µmol/L HcyH was increased by 
4.5-fold (to 118±16 monocytes/mm2, P<0.001 versus control cells; n=3), paralleling the increased adhesion of U937 cells. Methionine (500 µmol/L), the physiological Hcy precursor, caused a 2.3-fold increase in normal monocyte adhesion (to 60±17 monocytes/mm2, P<0.001 versus control cells, n=3; Figure 2). Folic acid (5 µmol/L) had no effect by itself on subsequent monocyte binding but significantly inhibited HcyH-induced monocyte adhesion by 50% (Figure 2). Importantly, stimulation of HAECs with 100 µmol/L L-cysteine, another sulfur-containing amino acid, had no effect on either normal or U937 monocyte adhesion (28±5 and 9±1 cells/mm2, respectively, versus control cells; n=3 and P>0.1 in both cases).
|
TNF- stimulation of HAECs, a positive control for the upregulation of EC adhesion molecule expression and induction of monocyte adhesion, markedly increased U937 and normal monocyte adhesion to these cells. With the use of U937 cells, HAECs that had been stimulated with 10 ng/mL TNF- for 18 hours bound 391±109 versus 9±1 cells/mm2 background (n=16 experiments, P<0.001 versus control cells; data not shown). By use of peripheral blood monocytes, HAECs that had been stimulated with 1 ng/mL TNF- for 18 hours bound 123±17 versus 26±6 cells/mm2 background (n=3 experiments, P<0.001 versus control cells; Figure 2). With 10 ng/mL TNF-, HAECs bound 217±17 normal monocytes (n=3, P<0.001; data not shown). Simultaneous HAEC stimulation with low-dose TNF- (1 ng/mL) and HcyH (200 µmol/L) resulted in a modest but significant (40%) increase in monocyte adhesion over the sum effect of both agents applied individually (n=3, P=0.011; Figure 2).
Because normal monocytes and U937 cells behaved qualitatively similarly and because 100 µmol/L HcyH maximally induced U937 monocyte adhesion without affecting EC viability, this cell line and HcyH dose were used in subsequent experiments. Because in kinetic studies (Figure 1, inset) the HcyH-induced monocyte adhesion occurred 4 hours after HAEC stimulation and was maximal between 12 and 24 hours, we stimulated HAECs for 18 hours in subsequent mechanistic studies.
HcyH Upregulates Endothelial Adhesion Molecule Function
Using neutralizing monoclonal antibodies against human ICAM-1, VCAM-1, and endothelial-leukocyte adhesion molecule (ELAM) (5 µg/mL for all), we evaluated their relative involvement in HcyH-induced monocyte adhesion to HAECs (Figure 3). Although anti–ICAM-1 monoclonal antibody caused a modest (11±9%, P=0.032; n=5), albeit significant, reduction of HcyH-induced U937 monocyte adhesion, anti–VCAM-1 and anti-ELAM monoclonal antibodies individually inhibited the number of adherent monocytes by 48±16% (P<0.001, n=5) and 39±17% (P=0.004, n=4), respectively. In TNF-–stimulated HAECs (10 ng/mL, 18 hours), anti–ICAM-1, anti–VCAM-1, and anti-ELAM monoclonal antibodies inhibited U937 monocyte adhesion by 25%, 40%, and 35%, respectively (not shown).
|
HcyH Upregulates VCAM-1 mRNA and Cell Surface VCAM-1 Protein Expression in HAECs
Consistent with the findings of the functional assays, using quantitative reverse transcription (RT)-PCR, we detected a 4.9±1.2-fold increase in VCAM-1 mRNA in HAECs stimulated with 100 µmol/L HcyH for 3 hours (P=0.027, n=2; Figure 4). By contrast, HcyH stimulation had no detectable effect on ICAM-1 mRNA levels in the same cells (P>0.08, not shown). By flow cytometry, stimulation with HcyH resulted in a modest, yet statistically significant, increase in VCAM-1 surface protein in HAECs versus control cells. The percentage of VCAM-1+ HAECs were 1% in unstimulated cultures and 2%, 3%, and 6% in HAECs that were stimulated for 24 hours with 10, 25, and 100 µmol/L HcyH, respectively (Table). In comparison, 5 hours of stimulation with 0.1, 1.0, and 10.0 ng/mL TNF- resulted in 12%, 23%, and 65% VCAM-1+ cells, respectively. VCAM-1 expression in HAECs was synergistically augmented when the cells were simultaneously exposed to HcyH and low concentrations of TNF-. For example, in HAECs exposed for 18 hours to 100 µmol/L HcyH and then additionally stimulated with 0.1 ng/mL TNF- for 5 hours, VCAM-1+ cells increased to 28% (P<0.01, n=4) compared with 6% and 12% for the same doses of HcyH and TNF- alone, respectively (Table).
|
|
Enhanced Monocyte Adhesion to HcyH-Activated ECs Is Abrogated by COX Inhibitors
Indomethacin, a nonselective COX-1/COX-2 antagonist, caused a concentration-dependent inhibition of HcyH-induced monocyte adherence to HAECs (Figure 5A). Importantly, at 10 µmol/L indomethacin, which approximates clinically attainable plasma levels (ie, 3 to 6 µmol/L), HcyH-induced adhesion was completely abrogated (P>0.1 versus unstimulated control cells, n=3). Similarly, acetylsalicylic acid (aspirin), another nonselective COX-1/COX-2 inhibitor, completely inhibited the HcyH effect at 10 µmol/L, also a pharmacologically relevant concentration (P>0.1, n=2). In contrast, NS-398, a highly selective COX-2 antagonist, only partially inhibited ( 38±8%) HcyH-mediated monocyte adhesion, even at 100 µmol/L, a concentration >10-fold above its reported IC50 for COX-2 inhibition (P<0.001, n= 3).15 At the concentrations used in the present study, these COX inhibitors neither modulated baseline monocyte adhesion nor were they cytotoxic to HAECs.
|
Enhanced Monocyte Adhesion to HcyH-Activated ECs Is Modulated by NO and ROS
An interrelationship exits between EC adhesion molecule expression and NO and ROS production.16,17 Incubation of HAECs with NG-monomethyl-L-arginine (L-NMMA, 100 µmol/L), a competitive inhibitor of endothelial NO generation, had no effect on basal or HcyH- mediated endothelial adhesiveness. Sodium nitroprusside (100 µmol/L), an exogenous NO donor, and excess L-arginine (1 mmol/L), the physiological substrate for NO production, caused moderate, yet significant, inhibition of HcyH-induced monocyte adhesion (Figure 5B). Scavenging free superoxide radicals with superoxide dismutase (SOD, 500 U/mL) significantly decreased monocyte adhesion in HcyH-treated HAECs (Figure 5). However, catalase (5000 U/mL), which catalyzes the conversion of hydrogen peroxide to water, either with or without SOD present, had no additional inhibitory effect.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Although tHcy is a recognized independent cardiovascular risk factor,1,3 the mechanisms by which it alters the physiology of the vascular wall remain largely unknown. Others have previously demonstrated Hcy-induced EC dysfunction, including altered proliferation6 and the expression of bioactive molecules.7,8 To date, however, the few studies investigating the potential role of Hcy in modulating leukocyte-endothelial interactions have largely focused on the potential involvement of ICAM-1, yielding, in part, controversial results.9,10,18,19 One notable exception is a recent report that demonstrated increased vascular VCAM-1 expression in hyperhomocysteinemic mice.20
Our primary finding is that HcyH is proinflammatory and upregulates the expression of HAEC adhesion molecules, specifically VCAM-1, resulting in enhanced monocyte adhesion. Although this primary effect is modest in terms of VCAM-1 steady-state mRNA and cell surface protein expression, it nonetheless is significant, resulting in 500% increased adhesion of normal and U937 monocytes to HcyH-stimulated HAECs. Methionine, the biological precursor to Hcy, but not cysteine, induces endothelial adhesiveness, indicating the specific action of HcyH. Additionally, folic acid, a coenzyme critical in metabolizing Hcy, reduced HcyH-induced monocyte adhesion by 50% (Figure 2). This finding is in line with recent reports wherein folate inhibited HcyH-induced VCAM-1 in murine atherosclerotic lesions,20 ameliorated moderately elevated plasma tHcy levels, and reduced neointimal formation in rats made hyperhomocysteinemic by methionine or HcyH feeding.21 Importantly, we found that HcyH acts in synergy with low concentrations of TNF- in upregulating VCAM-1 expression, suggesting that even modest elevations of tHcy might increase the basal activation state of ECs and, thereby, precondition the vessel wall to concomitant or subsequent injury by known proatherogenic/inflammatory agonists.
Neutralizing antibodies against VCAM-1 decreased HcyH-induced monocyte binding to HAECs by 50%, indirectly confirming increased functional VCAM-1 expression. Because VCAM-1 expression is focally elevated in ECs in vascular regions prone to atherogenesis,11,20 our findings might reflect a link between elevated tHcy levels and enhanced monocyte infiltration in developing atherosclerotic lesions. The partial efficacy of blocking antibodies against E-selectin and, to a lesser extent, ICAM-1 suggests that other adhesion molecules are also involved in the atherogenic activation of ECs by HcyH.
Consistent with the functional assay results, HcyH increased VCAM-1 gene and protein expression in HAECs. By quantitative RT-PCR, we observed a 5-fold increase in VCAM-1 mRNA levels in HAECs that had been treated with 100 µmol/L HcyH for 3 hours. By flow cytometry, HcyH significantly increased the VCAM+ fraction of HAECs. This could have important implications in atherogenesis, a chronic low-grade inflammatory state involving multiple bioactive mediators.
We used several pharmacological approaches to elucidate some of the possible mechanisms of HcyH action. Protein kinases C and A reportedly mediate cytokine-induced upregulation of EC adhesion molecule expression.22,23 However, in our system, neither inhibition of protein kinase C (10 to 50 µmol/L H7) nor inhibition of protein kinase A (50 µmol/L H89) nor elevation of intracellular cAMP in HAECs with use of the membrane-permeant mimetic dibutyryl cAMP had any effect on either baseline or HcyH-enhanced EC-monocyte interactions (not shown). Activated ECs can secrete IL-1, an inflammatory cytokine that can act in an autocrine fashion to induce adhesion molecules. However, anti–IL-1 neutralizing antibodies had no effect on monocyte adhesion (not shown), ruling out the possibility that the HcyH effect is mediated by autocrine IL-1.
By contrast, HcyH-induced monocyte binding to HAECs was completely abrogated by pretreating the endothelial monolayers with clinically relevant concentrations of common COX inhibitors. Aspirin and indomethacin, which are nonselective COX-1/COX-2 inhibitors, concentration-dependently inhibited the proinflammatory effect of HcyH. Specific inhibition of COX-2 with NS-398, even at concentrations more than an order of magnitude greater than its IC50,15 resulted in only partial (40%) inhibition of HcyH-induced adhesion. This suggests a greater relative importance of the COX-1 isoform in mediating this effect. Because the COX enzymes are responsible for the generation of several classes of vasoactive substances (ie, prostaglandins, thromboxanes, and prostacyclin), careful dissection of the molecular pathways downstream from COX will yield more insight into the specific mechanisms of HcyH-mediated inflammation.24 It is interesting to speculate that the commonly prescribed daily aspirin tablet, issued as a cardioprotective measure, might have the additional benefit of slowing atherogenesis by inhibiting HcyH-induced monocyte adhesion to the arterial lining. This could reflect a more general suppression of an otherwise proatherogenic EC phenotype.
Elevated plasma tHcy perturbs endothelial NO expression and activity in the vasculature.7,10,25 Although it is uncertain whether Hcy can modulate NO synthase expression,7,26 it clearly has the potential to complex with and inactivate released NO, 7,25 potentially forming cytotoxic peroxynitrate radicals. In vivo, HcyH- and tHcy-mediated NO downregulation is accompanied by measurably impaired vascular function.10,27 Elevated levels of NO downregulate cytokine-induced EC adhesion molecule expression.16,28 In our hands, L-arginine and nitroprusside attenuated (25% inhibition), but did not abrogate, HcyH-induced monocyte adhesion to HAECs. This is in line with evidence that elevated NO mitigates vasomodulatory aberrations in the vasculature28 and can partially reduce HcyH-induced leukocyte adhesion in vivo.10 In preliminary gene array studies of HcyH-stimulated HAECs, we saw no change in mRNA expression for the 3 known NO synthase isoforms (not shown). Thus, Hcy-induced endothelial VCAM-1 expression appears in part to be due to downregulated NO activity/bioavailability.
Hcy alters EC redox potentials, in part by downregulating intracellular glutathione peroxidase activity, resulting in accumulation of intracellular ROS.29 Additionally, superoxide can directly quench the activity of NO.30 In the present study, SOD pretreatment of ECs reduced HcyH-induced monocyte adhesion by 25%, whereas catalase was ineffective, suggesting that superoxide radicals, but not free hydrogen peroxide, may contribute to HcyH-induced adhesion molecule expression.
In summary, we demonstrated that HcyH markedly increases the adhesiveness of HAECs to monocytes and acts in synergy with inflammatory cytokines, such as TNF-. HcyH-induced upregulation of VCAM-1 mRNA and of functional protein on the EC surface is mediated by multiple signaling pathways, with their relative importance being COX-1>COX-2>NO=ROS. The finding that clinically relevant concentrations of proven COX inhibitors can completely abrogate HcyH-induced monocyte adhesion to ECs further supports their usefulness as part of the pharmacological arsenal that we are amassing against cardiovascular disease.
|
Acknowledgments |
|---|
This study was supported by a grant-in-aid from the American Heart Association National Center (No. 9750315N) to Dr Lelkes, by National Eye Institute grant EY06484 to Dr Rosenbaum, and by a National Institutes of Health predoctoral training grant to Matthew Silverman. We thank Michelle Bande-Sigfreid, Waukesha County Medical Examiner’s Office, Waukesha, Wis, for providing donor tissues, and Prof R. Auerbach, University of Wisconsin-Madison, for generously providing facilities for conducting some of these studies.
|
Footnotes |
|---|
* These authors contributed equally to the present study.
Presented in part at the 1st Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, Denver, Colo, May 2000, and at the NATO Advanced Study Institute, Crete, Greece, July 2000.
Received November 2, 2001; accepted February 15, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999; 354: 407–413.[CrossRef][Medline] [Order article via Infotrieve]
2. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985; 37: 1–31.[Medline] [Order article via Infotrieve]
3.
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995; 274: 1049–1057.
4. Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis. 1996; 122: 201–216.[CrossRef][Medline] [Order article via Infotrieve]
5.
Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol. 1999; 19: 2922–2927.
6. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis. 1996; 122: 163–172.[CrossRef][Medline] [Order article via Infotrieve]
7. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol. 2000; 279: F671–F678.
8.
Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993; 13: 1327–1333.
9. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res. 999; 84: 409–416.
10. Pruefer D, Scalia R, Lefer AM. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. Gen Pharmacol. 1999; 33: 487–498.[CrossRef][Medline] [Order article via Infotrieve]
11.
Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
12. Kanda K, Hayman GT, Silverman MD, Lelkes PI. Comparison of ICAM-1 and VCAM-1 expression in various human endothelial cell types and smooth muscle cells. Endothelium. 1998; 6: 33–44.[Medline] [Order article via Infotrieve]
13.
Voraberger G, Schafer R, Stratowa C. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5' -regulatory region: induction by cytokines and phorbol ester. J Immunol. 1991; 147: 2777–2786.
14.
Polte T, Newman W, Gopal TV. Full length vascular cell adhesion molecule 1 (VCAM-1). Nucleic Acids Res. 1990; 18: 5901.
15. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994; 47: 55–59.[CrossRef][Medline] [Order article via Infotrieve]
16. Takahashi M, Ikeda U, Masuyama J, Funayama, Kano S, Shimada K. Nitric oxide attenuates adhesion molecule expression in human endothelial cells. Cytokine. 1996; 8: 817–821.[CrossRef][Medline] [Order article via Infotrieve]
17. Cominacini L, Garbin U, Pasini AF, Ravoli A, Campagnola M, Contessi GB, Pastorino AM, Lo Cascio V. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med. 1997; 22: 117–127.[CrossRef][Medline] [Order article via Infotrieve]
18.
Rohde LE, Hennekens CH, Ridker PM. Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men. Arterioscler Thromb Vasc Biol. 1999; 19: 1595–1599.
19. Tsakiris DA, Tschopl M, Jager K, Haefeli WE, Wolf F, Marbet GA. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Atherosclerosis. 1999; 142: 193–200.[CrossRef][Medline] [Order article via Infotrieve]
20. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001; 107: 675–683.[Medline] [Order article via Infotrieve]
21.
Morita H, Kurihara H, Yoshida S, Saito Y, Shindo T, Oh-hashi Y, Kurihara Y, Yazaki Y, Nagai R. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation. 2001; 103: 133–139.
22. Mattila P, Majuri ML, Mattila PS, Renkonen R. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. Scand J Immunol. 1992; 36: 159–165.[CrossRef][Medline] [Order article via Infotrieve]
23.
Ghersa P, Hooft van Huijsduijnen R, Whelan J, Cambet Y, Pescini R, DeLamarter JF. Inhibition of E-selectin gene transcription through a cAMP-dependent protein kinase pathway. J Biol Chem. 1994; 269: 29129–29137.
24. Quere I, Habib A, Tobelem G, Maclouf J. Inhibition of cyclooxygenase activity in human endothelial cells by homocysteine. Adv Prostaglandin Thromboxane Leukot Res. 1995; 23: 397–399.[Medline] [Order article via Infotrieve]
25.
Ungvari Z, Pacher P, Rischak K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 1999; 19: 1899–1904.
26. Upchurch GR Jr, Welch GN, Fabian AJ, Pigazzi A, Keaney JF Jr, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis. 1997; 132: 17–185.
27.
Chao CL Kuo TL, Lee YT. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults. Circulation. 2000; 101: 485–490.
28.
Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A. 1996; 93: 9114–9119.
29.
Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997; 272: 17012–17017.
30. McQuaid KE, Keenan AK. Endothelial barrier dysfunction and oxidative stress: roles for nitric oxide? Exp Physiol. 1997; 82: 369–376.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  W. G. Christen, R. J. Glynn, E. Y. Chew, C. M. Albert, and J. E. Manson Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women: The Women's Antioxidant and Folic Acid Cardiovascular Study Arch Intern Med, February 23, 2009; 169(4): 335 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sen, N. Tyagi, M. Kumar, K. S. Moshal, W. E. Rodriguez, and S. C. Tyagi Cystathionine- -synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1779 - C1787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Carluccio, M. A. Ancora, M. Massaro, M. Carluccio, E. Scoditti, A. Distante, C. Storelli, and R. De Caterina Homocysteine induces VCAM-1 gene expression through NF-{kappa}B and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2344 - H2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Prontera, N. Martelli, V. Evangelista, E. D'Urbano, S. Manarini, A. Recchiuti, A. Dragani, C. Passeri, G. Davi, and M. Romano Homocysteine Modulates the CD40/CD40L System J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2182 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O. Apostolov, S. V. Shah, E. Ok, and A. G. Basnakian Carbamylated Low-Density Lipoprotein Induces Monocyte Adhesion to Endothelial Cells Through Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 826 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Postea, F. Krotz, A. Henger, C. Keller, and N. Weiss Stereospecific and Redox-Sensitive Increase in Monocyte Adhesion to Endothelial Cells by Homocysteine Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 508 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suhara, K. Fukuo, O. Yasuda, M. Tsubakimoto, Y. Takemura, H. Kawamoto, T. Yokoi, M. Mogi, T. Kaimoto, and T. Ogihara Homocysteine Enhances Endothelial Apoptosis via Upregulation of Fas-Mediated Pathways Hypertension, June 1, 2004; 43(6): 1208 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matetzky, D. Freimark, S. Ben-Ami, I. Goldenberg, J. Leor, R. Doolman, I. Novikov, M. Eldar, and H. Hod Association of Elevated Homocysteine Levels With a Higher Risk of Recurrent Coronary Events and Mortality in Patients With Acute Myocardial Infarction Arch Intern Med, September 8, 2003; 163(16): 1933 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Stam, C. van Guldener, C. G. Schalkwijk, P. M. ter Wee, A. J. M. Donker, and C. D. A. Stehouwer Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity Nephrol. Dial. Transplant., May 1, 2003; 18(5): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||